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Alteration of Multiple Leukocyte 
Gene Expression Networks is 
Linked with Magnetic Resonance 
Markers of Prognosis After Acute 
ST-Elevation Myocardial Infarction
A. Teren1,2,3,*, H. Kirsten2,4,5,*, F. Beutner1,2,3, M. Scholz2,4, L. M. Holdt2,6, D. Teupser2,6, 
M. Gutberlet7, J. Thiery2,3, G. Schuler1,2 & I. Eitel8
Prognostic relevant pathways of leukocyte involvement in human myocardial ischemic-reperfusion 
injury are largely unknown. We enrolled 136 patients with ST-elevation myocardial infarction (STEMI) 
after primary angioplasty within 12 h after onset of symptoms. Following reperfusion, whole blood 
was collected within a median time interval of 20 h (interquartile range: 15–25 h) for genome-wide 
gene expression analysis. Subsequent CMR scans were performed using a standard protocol to 
determine infarct size (IS), area at risk (AAR), myocardial salvage index (MSI) and the extent of late 
microvascular obstruction (lateMO). We found 398 genes associated with lateMO and two genes with 
IS. Neither AAR, nor MSI showed significant correlations with gene expression. Genes correlating 
with lateMO were strongly related to several canonical pathways, including positive regulation 
of T-cell activation (p = 3.44 × 10−5), and regulation of inflammatory response (p = 1.86 × 10−3). 
Network analysis of multiple gene expression alterations associated with larger lateMO identified the 
following functional consequences: facilitated utilisation and decreased concentration of free fatty 
acid, repressed cell differentiation, enhanced phagocyte movement, increased cell death, vascular 
disease and compensatory vasculogenesis. In conclusion, the extent of lateMO after acute, reperfused 
STEMI correlated with altered activation of multiple genes related to fatty acid utilisation, lymphocyte 
differentiation, phagocyte mobilisation, cell survival, and vascular dysfunction.
Despite early flow restoration in epicardial coronary arteries, the magnitude of myocardial injury varies substan-
tially in patients with ST-elevation myocardial infarction (STEMI). One of the major determinants of final infarct 
size and cardiomyocyte death is myocardial reperfusion injury during/after reperfusion of the infarcted vessel1. 
The pathophysiology of reperfusion injury is multifactorial and includes distal embolization/platelet plugging of 
the microvasculature, release of toxic inflammatory mediators, production of oxygen free radicals, and accumu-
lation of intracellular calcium2.
Despite the well-known prognostic relevance of systemic and local inflammatory response for reperfusion 
injury, data regarding specific molecular markers of the inflammatory response triggered by acute myocardial 
ischemia are limited. Particularly, leukocyte-driven inflammation plays an essential role in the pathophysiology 
of reperfusion injury and adverse remodelling in infarcted myocardium3–6. Leukocyte gene expression patterns as 
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assessed by genome-wide transcriptome analysis may therefore provide further insights into the pathophysiology 
of systemic and microvascular myocardial changes after STEMI with potential diagnostic or even therapeutic 
relevance.
Cardiovascular magnetic resonance (CMR) has emerged as a promising non-invasive imaging modality for 
in-vivo assessment of myocardial damage after STEMI. CMR enables a precise quantification of infarcted and sal-
vaged myocardium, both relevant for the prognosis after STEMI7. Furthermore, CMR is able to directly visualise 
microvascular obstruction (MO), a marker of severe reperfusion injury, which is strongly associated with adverse 
clinical outcome after STEMI independent from infarct size8. However, little is known about the complex molec-
ular processes that associate with the severe myocardial and microvascular tissue damage as visualized by CMR. 
Therefore, our aim was to identify links between CMR-markers of myocardial damage after acute reperfused 
STEMI and alterations of the transcriptome on gene- and pathway level in peripheral blood mononuclear cells 
(PBMC).
Materials and Methods
Study population. Patients recruited in this cross sectional trial are participants of the ongoing LIFE-Heart 
study9 admitted for acute STEMI as the first manifestation of coronary artery disease. All participants underwent 
a full CMR-scan after interventional reperfusion therapy for comprehensive assessment of myocardial damage at 
day 1–4 after infarction.
The study meets the ethical standards of the Declaration of Helsinki. It has been approved by the Ethics 
Committee of the Medical Faculty of the University of Leipzig, Germany (Reg. No 276–2005) and is registered 
by ClinicalTrials.gov (NCT00497887). Written informed consent including agreement with CMR imaging, and 
genetic analyses has been obtained from all participants enrolled in the study. All methods were carried out in 
accordance with the relevant guidelines and regulations.
The recruitment phase of the trial was conducted at a single tertiary care centre between August 2008 and 
November 2010. Patients with infarction undergoing primary percutaneous coronary intervention (PCI) were 
eligible if the onset of symptoms was less than 12 h before PCI and if they had ST-segment elevation of at least 
0.1 mV in ≥ 2 extremity leads or at least 0.2 mV in ≥ 2 precordial leads. To ensure that CMR findings reflected 
acute myocardial injury, patients were not enrolled if they had a previous myocardial infarction (MI). Further 
exclusion criteria were previous fibrinolysis and patients with contraindications to CMR at study entry such as 
implanted pacemakers, defibrillators, claustrophobia, or metallic intracranial implants.
Primary angioplasty and subsequent treatment. Primary PCI was performed according to standard 
clinical practice. The decision to use bare-metal or drug-eluting stents was left to the discretion of the inter-
ventional cardiologist. All patients received 500 mg of aspirin and heparin (60 U/kg body weight) intravenously 
before PCI. Clopidogrel or Prasugrel (600 mg or 60 mg orally during PCI, if not administered before, followed 
by 75 mg/day or 10 mg/day for at least 12 months, respectively) was mandatory. Aspirin was given indefinitely 
at a dose of 100 mg/day. The use of glycoprotein IIb/IIIa inhibitors, angiotensin-converting enzyme inhibitors, 
beta-blockers, and statins was strongly recommended according to guidelines10.
Angiographic analysis and electrocardiographic analysis. Coronary angiography of the target lesion 
was performed before and after PCI using standards and projections described elsewhere in detail7. For electro-
cardiographic interpretation, the cumulative ST-segment resolution approximately 90 min after PCI, expressed 
as the percentage, was calculated by 2 blinded observers as described previously11. Categorization was performed 
in complete (≥ 70%), partial (< 70% to 30%), and no (< 30%) ST-segment resolution2.
CMR. CMR was performed on days 1 to 4 after the index event (median time interval of 61 h IQR 44–89 h) 
using a 1.5-T scanner (Intera CV, Philips Medical Systems, Best, The Netherlands). The well-established infarction 
protocol includes the assessment of left ventricular (LV) function, mass, volumes, myocardial salvage, infarct size 
and MO7.
For area at risk determination, short-axis slices covering the whole ventricle using a T2-weighted triple inver-
sion recovery breath-hold pulse sequence were obtained using a body coil. Late enhancement images cover-
ing the whole ventricle were acquired approximately 15 min after intravenous administration of 0.2 mmol/kg 
body weight of gadobutrol to assess late MO, and IS (Gadovist, Bayer Schering Pharma, Berlin, Germany). A 
3-dimensional inversion recovery turbo gradient echo was used for image acquisition.
Image analysis. For all quantitative analyses, certified CMR evaluation software was used (cmr42 Circle 
Cardiovascular Imaging Inc., Calgary, Alberta, Canada). Semi-automated computer-aided threshold detection 
was used to identify regions of edema, late MO, and infarcted myocardium. A myocardial region was regarded 
as affected if at least 10 adjacent myocardial pixels revealed a signal intensity of > 2 standard deviations (SD) of 
remote myocardium for edema and > 5 SDs in late enhancement images for infarct size (IS)12. IS, area at risk, and 
MO were expressed as percentages of left ventricular mass (% LV), as previously described7. If present, MO was 
included in the overall IS analysis and was also quantified separately. This procedure resulted in following param-
eters: a) infarct size as percentage of LV mass (IS), b) area at risk as percentage of LV mass (AAR), c) myocardial 
salvage index (MSI), i.e. AAR-IS/AAR * 100, and d) late MO as percentage of LV mass. For modelling of late MO 
as function of gene expression levels, we classified patients in the following three groups:
1. patients with no visualised late MO; 2. patients with late MO < MOmedian; 3. patients with late 
MO ≥ MOmedian. The CMR core laboratory has excellent reproducibility and low interobserver and intraobserver 
variability for IS and MSI assessment7.
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Measurement of gene-expression. In each patient, whole blood was collected (median time interval of 
20 h IQR 15–25 h), and further processed to isolate PBMCs for genome-wide gene-expression analysis. Upon 
immediate centrifugation, samples were stored at 4 °C and transported within 5 hours for PBMC isolation using 
cell preparation tubes (CPT, Becton Dickinson). Multiple aliquots of PBMCs were stored at − 80 °C or liquid 
nitrogen for further analysis13. Total RNA was extracted from PBMC using TRIzol reagent (Invitrogen). 500 ng 
of RNA (quantified with NanoDrop, Thermo Fisher) were ethanol precipitated applying GlycoBlue (Invitrogen). 
Gene expression was measured using the HT-12 v4 Expression BeadChip of Illumina (Illumina, San Diego, CA, 
USA). Wet-lab processing comprised RNA clean-up, precipitation, probe synthesis, hybridisation and scanning 
of hybridized arrays in accordance to the specification of the manufacturer14. Raw data of all 47,323 probes was 
extracted by Illumina BeadStudio, 47,308 probes could be successfully imputed in all samples. Data was fur-
ther processed in R/Bioconductor15. Individuals with atypical numbers of expressed genes (median ± 3 inter-
quartile ranges (IQR)) were excluded (0.9%). Transcripts not expressed according to Illumina’s cut-off p ≤ 0.05 
in at least 50% of all samples were not considered in the analysis. Expression data were quantile normalised 
and log2-transformed16. Individuals with atypical expression patterns (quantified as Euclidian distance between 
expression levels of all individuals and an artificial individual defined as the average of all samples after remov-
ing 10% samples farthest away from the average of all samples) were excluded (1.2%, having a distance larger 
than median + 3 IQR. To further exclude technical artefacts, we defined for each individual a combined score 
including Illumina’s internal quality control features available for HT-12 v4 quantified as Mahalanobis-distance 
between all individuals and an artificial individual with average values for these parameters. We excluded atyp-
ical individuals with a distance > median + 3 IQR (0.2%). Transcripts were adjusted for known batch effects 
(Sentrix. ID) applying an empirical Bayes method17. Thereby, transcripts still inflated after adjustment according 
to Bonferronis criteria were excluded. Probes were assigned to genes using Entrez-gene IDs. In consequence, 136 
individuals were analysed for 13,483 gene expression probes corresponding to 9,949 unique genes.
Statistical analysis. Association analysis of late MO as dependent variable with gene expression levels was 
analysed applying ordered multinomial regression using trichotomized values of late MO as described above. This 
analysis fully accounts for the non-normal distrubtion of MO values as about 46% of all patients had no visualised 
late MO, a characteristic that excludes standard linear regression analysis. Association of IS, AAR, and MSI with 
gene expression levels was done using linear regression. If not stated otherwise, all analyses were adjusted for age, 
gender, balloon-to-blood time, and balloon-to-CMR time. Thereby, we had 80% power to detect an assocation 
where gene-expression explains 15%, 18%, and 21% of the investigated variable at a p-value level of 1 × 10−4, 
1 × 10−5, 1 × 10−6, respectively. To control multiple testing, we used the false discovery rate (FDR) approach 
implying default FDR ≤ 5% level of control18. This approach has been shown to robustly control for multiple 
testing in genome-wide gene expression analysis19,20.
For KEGG-pathway- and gene ontology (GO)-based gene enrichment analysis we performed hypergeometric 
tests as implemented in the R package “GOstats”21,22. All genes surviving pre-processing were used in enrichment 
analysis as background. Network and functional pathway activation analyses was done with QIAGEN’s Ingenuity 
Pathway Analysis (IPA® , QIAGEN Redwood City, www.qiagen.com/ingenuity) using default settings.
Results
Patient characteristics. In total, 136 patients fulfilled the inclusion criteria of the study and completed 
all required laboratory and CMR assessments. The baseline clinical and laboratory characteristics of our study 
cohort are presented in Tables S1 and S2 in detail including times between pain onset and reperfusion, gene 
expression measurement as well as CMR. In 54.4% of patients, late MO could be detected by CMR. Patients with 
no, low, or a high extent of late MO showed significant between-group differences in all remaining prognostic 
determinants considered in the study (Table 1). Detailed, patients with increased late MO had a higher Gensini 
score, lower TIMI flow before PCI, lower degree of ST-segment resolution after PCI, and lower ejection fraction 
in echocardiography. In patients with larger late MO, aldosterone antagonists were more frequently administered 
(Table S1). In the routine biochemical and haematological analyses, patients with distinct severity of late MO 
differed significantly for CK-MB, ntproBNP, hsCRP levels, and in white blood cell count (Table S2). No significant 







Late MO < median 
(N = 37)
Late MO ≥ median 
(N = 37) p-value
MR-EF 49.6 (43.6–56.5)
54.2 
(48.6–59.7) 47.9 (43.8–52.3) 41.3 (34.9–51.0) < 0.001
AAR (%LV) 33.6 (24.9–49.5)
31.9 
(20.3–43.5) 32.5 (26.2–39.1) 48.0 (34.3–56.0) 0.002
IS (%LV) 19.2 (11.1–25.7)
12.3 
(3.1–20.4) 19.0 (14.6–22.1) 30.0 (24.7–41.4) < 0.001
MSI (%AAR) 43.8 (27.4–62.3)
58.1 
(36.6–87.5) 47.3 (28.5–56.8) 30.0 (10.6–39.5) < 0.001
Table 1.  Cardiovascular magnetic resonance characterization of the study sample. *Values are given as 
number (%) or median (P25–P75). Late MO – late microvascular obstruction; MR-EF – ejection fraction 
assessed by magnetic resonance; AAR – area at risk; IS – infarct size; MSI – myocardial salvage index; p-value – 
result of Kruskal-Wallis test comparing three groups of late MO.
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Overview of associations between PBMC gene-expression and CMR. A summary of associ-
ations between adjusted gene expression profiles and considered CMR surrogate markers of clinical outcome 
is given in Table 2. As anticipated, significant relationship was found between all considered CMR parameters 
(Supplementary Figure 1).
Both late MO and IS showed relevant relation to gene expression levels whereas no associations at FDR ≤ 5% 
with AAR and MSI were found. To further investigate this finding, we analysed the distribution of test statistics. 
This information can be used to estimate the number of genes that are correlated with CMR surrogate markers 
even when effect sizes of genes are too small to achieve significance at a FDR ≤ 5%. From this analysis we estimate 
that a large number of genes is associated also with IS, AAR and MSI. Detailed, about a third of all expression 
probes were related with late MO (eta1 = 35.7%), whereas for the CMR markers MSI, IS, and AAR about a quarter 
of transcripts were associated, though with smaller effect sizes (Table 2).
Gene expression changes related to late microvascular obstruction and infarct size. In detail, 
398 genes correlated at FDR ≤ 5% with late MO (minimal p – value = 3.51 × 10−6, Tables 3 and S3). Upon 
additional adjustment of these gene associations for smoking, LDL levels, BMI levels, the presence of diabe-
tes mellitus, arterial hypertension, symptom-to-reperfusion time and C-reactive protein, the effect did not 
change significantly (p – value > 0.2). Functional classification of these genes is summarised in Table S4, respec-
tively. In the subsequent pathway analysis, 202 of these genes (50.6%) could be related to a canonical biological 
pathways from GO and KEGG, summarised in Table S5. Among central pathways with the highest enrich-
ment were: metabolism (p = 2.21 × 10−6), positive regulation of alpha-beta T cell activation (p = 3.44 × 10−5), 
oxidation-reduction process (p = 2.18 × 10−3), inflammatory response (p = 4.52 × 10−3), antigen processing and 
presentation of peptide antigen via major histocompatibility complex (MHC) class I (p = 1.69 × 10−2), epigenetic 
regulation of gene expression (2.53 × 10−2), response to interferon-gamma (p = 2.67 × 10−2), and protein trans-
port (p = 2.80 × 10−2).
Association analysis between gene expression levels and IS revealed two significant genes at FDR 5%, 
Complement Component (3b/4b) Receptor 1 (CR1) and Interferon Alpha/Beta Receptor 1 (IFNAR1). Both genes 
were associated with late MO at FDR values = 2.9% and 6.3%, respectively.
Prediction of functional downstream effects of associated genes. To further identify functional 
consequences of changes in gene expression levels associated with different levels of late MO and the other CMR 
parameters, we performed pathway activation analysis of gene expression networks. Using this approach, we 
made inferences whether identified enriched pathways are activated or suppressed in the presence of larger late 
MO levels.
Firstly, we made prediction for the 100 genes showing the strongest association with late MO (Fig. 1a and b). 
For more severe late MO, expression patterns of these genes were predicted to result in increased utilisation and 
subsequent decreased concentration of fatty acid (prediction z-score − 1.968; enrichment-p-value = 5.27 × 10−3), 
repressed cell differentiation (z-score − 1.480; p = 9.66 × 10−3), and decreased myeloid cell count (z-score − 1.400; 
p = 4.87 × 10−2). Furthermore, the observed expression changes were predicted to induce the inflammatory 
response (z-score 1.480; p = 1.92 × 10−2), and cell death (z-score 1.480; p = 1.92 × 10−2, Fig. 1a).
To identify an upstream factor that might have caused these predicted downstream effects, upstream regulator 
analysis was additionally performed. Here, tumor necrosis factor (TNF) was suggested to modulate the inflamma-
tory response by upregulating the expression of seven distinct late MO – associated genes (Fig. 1b).
Next, we performed the analogous prediction analysis with focus on phenotypes specific for cardiovascu-
lar system, therefore considering the top 200 genes associated with late MO. Multiple links with following pro-
cesses were identified: promotion of vascular disease (z-score 0.681; p = 2.00 × 10−2), increased proliferation of 
endothelial cells (z-score 2.157; p = 9.53 × 10−3), and activation of vasculogenesis (z-score 2.262; p = 1.43 × 10−2) 
(Fig. 2). Cellular and functional consequences of detected gene expression changes PBMC related to lateMO are 
summarised in Fig. 3.
Discussion
To our best knowledge, this is the first study characterising global PBMC-specific expression changes in asso-
ciation with established CMR markers of myocardial damage after acute reperfused STEMI. Our sample of 136 
detailed phenotyped patients allowed a robust identification of associated genes with moderate effect sizes and 
Phenotype
Characteristics of gene expression associations
min. pval min. qval FDR ≤ 5% eta1
late MO (% LV mass) 3.51 × 10−6 0.024 398 35.7%
IS (%LV mass) 2.76 × 10−6 0.027 2 27.1%
AAR (% LV mass) 1.44 × 10−5 0.125 0 25.4%
MSI 1.59 × 10−5 0.150 0 25.6%
Table 2.  Summary of association between PBMC gene expression profile and prognostic marker of 
outcome in patients after reperfused STEMI (n = 136). 1min. p:pval minimal p – value, min. q – val: minimal 
qvalue (i.e. FDR); FDR ≤ 5%: number of associated genes at the  default FDR ≤ 5% level of control; estimated 
percentage of truepositive findings of all 13,486 probes/9,949 genes that could be detected with a very large 
sample.
www.nature.com/scientificreports/




Function according to the gene 
cards (http://www.genecards.org/) p-value FDR OR (95% CI)
WSB2 55884 WD Repeat And SOCS Box Containing
modulation of IL21 signal 
transduction; recognition 
of substrates for ubiquitin-
proteasome- mediated protein 
degradation




activation protein ɣ 
signal transduction by 
binding phosphoserine or 
phosphothreonine motif adaptor 
protein
5.44 × 10−6 2.36 × 10−2 40.31  (8.19–198.34)
MCU 90550 mitochondrial calcium uniporter
mediates calcium uptake into 
mitochondria 1.10 × 10
−5 2.57 × 10−2 3.57  (25.12–4483.05)
FSTL3 10272 follistatin-like 3 (secreted glycoprotein)
binding and antagonizing protein 
members of the TGF-beta family – 
27ctiving, BMP2 and MSTN
1.44 × 10−5 2.62 × 10−2 102.81  (12.67–834.05)
LOC728855 728855 LOC728855 unknown function 1.51 × 10−5 2.63 × 10−2 0.04 (0.01–0.18)
DNAJB1 3337 DnaJ (Hsp40) Homolog, Subfamily B, Member 1 molecular chaperone 2.16 × 10
−5 2.69 × 10−2 0.06 (0.02–0.22)
MGST1 4257 microsomal glutathione S-transferase 1
membrane protection against 
oxidative stress 3.40 × 10
−5 2.74 × 10−2 8.50 (3.09–23.40)
GOLGA8B 440270 golgin A8 family, member B maintaining Golgi structure 3.72 × 10−5 2.74 × 10−2 0.11 (0.04–0.31)
SKAP2 8935 src kinase associated phosphoprotein 2
putatively involved in B-cell and 
macrophage adhesion processes 3.97 × 10
−5 2.75 × 10−2 19.53  (4.73–80.63)
RPL26L1 51121 ribosomal protein L26-like 1 by similarity structural constituent of ribosome 4.94 × 10
−5 2.77 × 10−2 153.20  (13.49–1740.14)
ATF6 22926 activating transcription factor 6
activating unfolded protein 
response target genes during 
endoplasmic reticulum stress
5.67 × 10−5 2.77 × 10−2 38.25  (6.49–225.49)
PLAC8 51316 placenta-specific 8
regulation of autophagy by 
facilitating the lysosome-
autophagosome fusion
6.93 × 10−5 2.78 × 10−2 11.13  (3.40–36.50)
VWA5A 4013 von Willebrand factor A domain containing 5 A putatively tumor supressor 7.93 × 10
−5 2.79 × 10−2 158.77  (12.82–1966.87)
CYFIP1 23191 cytoplasmic FMR1 interacting protein 1
in protein complex mediates 
translation repression and actin 
reorganisation
8.26 × 10−5 2.79 × 10−2 20.25  (4.53–90.56)




8.37 × 10−5 2.79 × 10−2 40.20  (6.38–253.28)
TH1L 51497 Negative Elongation Factor Complex Member C/D
negatively regulates the elongation 
of transcription by RNA polymerase 
II
8.79 × 10−5 2.79 × 10−2 0.01 (0.00–0.10)
IDH1 3417 Isocitrate Dehydrogenase 1 (NADP+ ), Soluble
oxidative decarboxylation of 
isocitrate to 2-oxoglutarate 8.83 × 10
−5 2.79 × 10−2 14.31  (3.78–54.14)
ST3GAL1 6482 ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 1
catalyzes the transfer of sialic acid to 
galactose-containing substrates 9.30 × 10
−5 2.80 × 10−2 0.04 (0.01–0.19)
TMEM167A 153339 Transmembrane Protein 167 A early part of secretory pathway 9.36 × 10−5 2.80 × 10−2 10.32  (3.20–33.29)
SEC23B 10483 Sec23 Homolog B  (S. Cerevisiae)
protein transport from the 
endoplasmic reticulum to the Golgi 
apparatus
9.40 × 10−5 2.80 × 10−2 78.77  (8.80–704.67)
CD83 9308 CD83 Antigen positive regulation of antigen presentation 9.43 × 10









9.47 × 10−5 2.80 × 10−2 19.38  (4.37–85.82)
CD36 948 CD36 Molecule (Thrombospondin Receptor)
scavenger receptor binds to 
collagen, thrombospondin, anionic 
phospholipids, long-chain fatty 
acids and oxidized LDL
9.50 × 10−5 2.80 × 10−2 10.10  (3.16–32.25)
ECRP 643332
ribonuclease, Rnase A family, 
2 (liver, eosinophil-derived 
neurotoxin) pseudogene
lncRNA of unknown function 9.54 × 10−5 2.80 × 10−2 3.55 (1.88–6.69)
ITPKB 3707 inositol-Trisphosphate 3-Kinase B modulation of cellular signalling 9.91 × 10
−5 2.80 × 10−2 0.02 (0.00–0.15)
Table 3.  Top 25 transcripts associating with the late MO assessed by CMR at FDR ≤ 5%. *For a full list of all 
398 genes with FDR ≤ 5% see Table S3. OR (95% CI) – estimated odds ratio with 95% confidence interval from 
the ordered multinomial regression model with gene expression as predictor and stratified late MO as response 
variable.
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related mechanisms. The main findings are: 1. late MO showed strong association with PBMC transcription 
patterns after STEMI; 2. expression levels associated with larger myocardial damage modulate lipid metabolism, 
inhibit the differentiation of lymphocytes, promote cell death, and mobilise phagocytes, resulting in inflamma-
tion, vascular dysfunction and induction of compensatory vascular repair. Consequently, our data contributes 
to the understanding of the molecular pathophysiology of mononuclear cells during the post-infarction period 
suggesting plausible links of the transcriptome to MO, a potent prognostic marker after STEMI.
Mononuclear cell gene expression patterns and late microvascular obstruction. We found the 
strongest association between gene expression in mononuclear cells and late MO yielding 398 transcripts corre-
lating with late MO at the level of FDR 5% suggesting multiple candidates for molecular markers of reperfusion 
injury. (Tables S3 and S4). From the distribution of all p-values, we estimate that in total about 35.7% of all inves-
tigated genes are related with late MO (Table 2). Changes in gene expression of PBMC after reperfused STEMI 
were previously demonstrated in the study of Kiliszek et al. comparing 28 STEMI patients with 14 patients having 
stable coronary artery disease (CAD)23. The authors identified 24 relevant genes, from which we also found eight 
significantly associated at FDR ≤ 5% and 20 at FDR ≤ 20% with late MO. This is considerably more than expected 
by chance (pexact < 10−5 for each of both comparisons) and validates our findings. Another study explored the 
relationship between peripheral blood gene expression patterns and incident cardiovascular death in 338 patients 
with suspected or confirmed CAD including 60 (18%) patients admitted for an acute MI. Reported gene expres-
sion signature for cardiovascular death was in substantial overlap with expression changes found in patients with 
acute MI24. In the present data, 21 of signature genes reported by Kim et al. exhibited the relationship between 
expression level and late MO. More recently, a set of 559 differentially expressed genes was identified in whole 
blood of patients after first-time acute MI when contrasting 5 and 22 patients with and without recurrent cardi-
ovascular events, respectively25. Our study corroborates pathophysiologic relevance of some of these genes and 
identifies additional novel genes and possible mechanisms. Concretely, we observed positive correlation of late 
MO with expression of several genes enhancing lipid synthesis from newly synthetized fatty acids, including 
cytosolic NADP-Isocitrate Dehydrogenase (IDH1), and the reported gene stearoyl-CoA desaturase (SCD) involved 
in synthesis of oleic acid25,26. Moreover, we found a negative correlation between another reported gene T-cell acti-
vation RhoGTPase activating protein (TAGAP) and late MO. TAGAB promotes T-cell activation (Table S6). In line 
with this data, expression changes of many additional genes promoting differentiation and activation of T-cells, 
and NK-cells, were correlated with reduced late MO, suggesting a protective role of these cells against ischemia 
- reperfusion (I/R) injury. Exemplarily, our strongest associated gene WD repeat and SOCS box containing 2 
(WSB2) was recently shown to downregulate the expression of the interleukin-21 receptor (IL21R)27, an important 
mediator of T-cell and NK-cell differentiation28. Patients with more severe late MO showed significantly higher 
Figure 1. Interaction network of (a) top downstream and (b) top upstream predicted functional consequences 
from gene expression level changes of the 100 genes best associated with late MO. “Upregulated” refers to 
increasing gene expression levels when late MO increased and, vice versa, “Downregulated” refers to decreasing 
gene expression levels when late MO increased. Stars indicate genes with more than one expression probe - here, 
gene expression level changes correspond to the strongest associated expression probe. Full names of genes 
involved in both networks are listed in Table S3.
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expression of WSB2 (p = 3.5 × 10−6, FDR < 5%, Table 3), and nominally lower expression of IL21R (p = 0.01 
corresponding to FDR < 9%).
A reperfusion-associated inflammation and microvascular dysfunction after STEMI is promoted by infiltrat-
ing neutrophils29. Expression levels of potent neutrophil chemotactic factors N-formyl peptide receptor (FPR2), 
Figure 2. Interaction network of predicted activated or inhibited cardiovascular functions from expression 
level changes of the 200 genes best associated with late MO. “Upregulated” refers to increasing gene 
expression levels when late MO increased and, vice versa, “Downregulated” refers to decreasing gene expression 
levels when late MO increased. Stars indicate genes with more than one expression probe - here, gene expression 
level changes correspond to the strongest associated expression probe. Full names of genes involved in the 
network are listed in Table S3.
Figure 3. Schematic summary of functional consequences identified by gene expression network analysis 
related to altered late MO as shown in Figs 1 and 2.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:41705 | DOI: 10.1038/srep41705
S100 Calcium Binding Protein A12 (S100A12), and S100 Calcium Binding Protein A9 (S100A9) correlated posi-
tively with late MO (Fig. 1). Fittingly, FPR2 antagonists are currently being discussed as promising therapeutics 
in I/R injury30. Expression of both, S100A12, and S100A9, was previously shown to predict MACE in stable CAD, 
and acute MI, respectively31,32. Chemokine (C-C Motif) Receptor 2 (CCR2) that also correlated positively with late 
MO, is the major receptor for macrophage chemoattractant protein mediating the migration of monocytes at the 
side of inflammation. In one previous study, targeted silencing of CCR2 expression ameliorated infarct–associated 
inflammation and post-infarct left ventricular remodelling in mice33.
Distal embolization of plaque debris into small arterioles with subsequent thrombus formation represents a 
major pathomechanism of severe late MO34. Expression of several identified genes is linked with arterial occlu-
sion. This includes examples like coagulation factor 5 (proaccelerin, F5), and carboxyesterase 1 (CES1). CES1 
inactivates 80–95% of administered clopidogrel-prodrug in the liver35. Therefore, increased myocardial damage 
among STEMI patients with increased CES1 expression might result from increased arteriolar thrombotic occlu-
sion, caused by increased hydrolytic degradation of clopidogrel.
Finally, endothelial cell death contributes substantially to the extent of I/R injury36. Newly identified genes 
mitochondrial calcium uniporter (MCU), follistatin-Like 3 (Secreted Glycoprotein) (FSTL3), and LIM Domain 
Kinase 2 (LIMK2) are known to promote cell death and were previously linked to I/R injury. Concordantly, we 
found increased expression of all three genes among patients with more severe MO, and IS37–39, (Figs 1 and 3). In 
contrast, expression changes promoting endothelial cell proliferation and vasculogenesis were observed (Figs 2 
and 3), possibly indicating that counterbalancing mechanisms are initiated but with insufficient activation to 
prevent functional damage.
Mononuclear cell gene expression levels and infarct size, myocardial oedema, and myocar-
dial salvage index. In contrast to late MO, we found considerably less association with IS, AAR, and MSI. 
However, from the total distribution of p-values we estimate that about a quarter of all analysed genes is associ-
ated with each of IS, AAR, and MSI, although with effect sizes that are too small to be statistically significant at 
the FDR 5% level in our dataset. This finding is in line with our observation that frequently similar pathways are 
effected by altered gene expression in relation to IS, AAR, and MSI (Supplementary Figure 2) Therefore, larger 
sample sizes may be required for additional analyses for these three parameters.
Limitations
First, blood samples for microarray analysis were collected early after reperfusion whereas CMR phenotypes 
were measured up to three days later. Therefore, our analysis is limited to changes of the transcriptome that are 
relevant for impairments as revealed by CMR that become manifest within days after STEMI. Second, we did not 
investigate leukocyte gene expression in individuals without STEMI. The principal aim of the study was to iden-
tify links between gene expression in leukocytes and established CMR markers of myocardial injury after STEMI, 
irrespective to the baseline gene expression in unaffected individuals. Third, we found that in depth analysis of 
transcriptional changes related to IS, AAR, and MSI would requires larger study sample due to the small effect 
sizes. Therefore, we focussed in our study on gene expression changes and the resulting functional consequences 
at pathway level that are linked to late MO, where our study was well-powered. Fourth, our results are based on 
detecting the gene expression on RNA level without considering the translation into the protein. However, recent 
high throughput proteomic approaches revealed a robust relationship between the gene expression at the RNA 
and protein level40. Finally, although our study confirms known pathway activation states and provides novel 
hypothesis on genes and pathways linked to more severe STEMI, our analysis is association-based and not yet 
replicated in an independent setting. Hence, identified relations do not imply causation and should be further 
validated in future experimental work.
Conclusions
We found multiple relevant links between gene expression in PBMC and prognostic CMR markers of 
post-infarction myocardial damage. Several associated genes encode proteins involved in modulation of inflam-
mation, cell survival, and vascular function. For many molecules with previous experimental link to myocardial 
I/R injury, the present study provides the first corroborating evidence of these links in a clinical setting. Moreover, 
our analyses revealed several novel molecules and pathways suggesting their involvement in leukocyte-related 
pathophysiology during post-infarct period. Further studies are warranted to validate the clinical relevance of 
identified genes and networks for the prediction and improvement of outcome after STEMI.
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